Hyunbum Jang

The paper identifies recurrent signaling pathways in breast cancer using single-cell data and suggests drug combinations targeting these pathways.

This study reveals the structural basis of RanGAP1 regulation and catalysis in nuclear transport, showing how sumoylation and conformational changes coordinate GTP hydrolysis.

This study investigates how mutations in Rac2 alter its conformational dynamics and signaling, revealing distinct inactive and overactive states that impact cellular function.

The paper uses molecular dynamics simulations to show that double mutations in PI3K variants lead to more active conformations and drug-targetable cryptic pockets, suggesting a conformational selection strategy for drug development.

The paper identifies key molecular pathways and proteins associated with melanoma brain metastasis through genomic analysis and suggests therapeutic strategies targeting these pathways.

This study uses molecular dynamics simulations to show that ERK activation requires ordered phosphorylation events, with threonine phosphorylation as the second step being essential for catalytic activity.

This study identifies distinct allosteric networks in CDK4 and CDK6 that explain their differential kinase activity, inhibitor binding, and roles in cell cycle regulation and drug resistance.

The paper identifies a cryptic pocket in mTOR oncogenic variants through molecular dynamics simulations and suggests designing PI3K-like inhibitors to target this pocket for therapeutic benefit.

This paper develops a signaling-based method to identify optimal protein combinations for anticancer drug therapy, validated using patient-derived data and xenografts.

The paper identifies co-occurring mutation pairs in cancer genomes that are associated with metastasis and provides a tool for predicting metastatic potential.

This study compares neurodevelopmental disorders and cancer, finding shared pathways but differing in signaling strength and outcomes.

The paper investigates why cyclin-D/CDK4 drives the longer G1 phase while cyclin-E/CDK2 regulates the short G1/S transition, proposing slower activation for cyclin-D/CDK4 and faster for cyclin-E/CDK2, with implications for CDK4 inhibitor design.

The paper identifies a novel NRAS variant in a melanoma-prone family and shows it impairs MAPK/AKT signaling while enhancing PI3K signaling.

This study uses explicit solvent simulations to reveal how PTEN interacts with phosphoinositide-enriched membranes, elucidating its mechanism of activation and membrane anchoring.